Phase III randomized study comparing 5 or 10 μg per kg per day of filgrastim for mobilization of peripheral blood progenitor cells with chemotherapy, followed by intensification and autologous transplantation in patients with nonmyeloid malignancies

BACKGROUND : It is not known whether increasing the dose of filgrastim after mobilizing chemotherapy improves collection of peripheral blood progenitor cells (PBPC) and leads to faster hematopoietic engraftment after autologous transplantation.

[1]  E. Shpall,et al.  Ex vivo expanded peripheral blood progenitor cells provide rapid neutrophil recovery after high-dose chemotherapy in patients with breast cancer. , 2000, Blood.

[2]  J. Crawford,et al.  Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  P. Pedrazzoli,et al.  Therapeutic relevance of CD34 cell dose in blood cell transplantation for cancer therapy. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  K. Schulman,et al.  Randomized trial of filgrastim, sargramostim, or sequential sargramostim and filgrastim after myelosuppressive chemotherapy for the harvesting of peripheral-blood stem cells. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  J. Reiffers,et al.  Abrogation of post-myeloablative chemotherapy neutropenia by ex-vivo expanded autologous CD34-positive cells , 1999, The Lancet.

[6]  A. Grañena,et al.  Stem cell factor in combination with filgrastim after chemotherapy improves peripheral blood progenitor cell yield and reduces apheresis requirements in multiple myeloma patients: a randomized, controlled trial. , 1999, Blood.

[7]  K. Schulman,et al.  Effect of CD34(+) cell dose on resource utilization in patients after high-dose chemotherapy with peripheral-blood stem-cell support. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  A. Fattorossi,et al.  Erythropoietin addition to granulocyte colony-stimulating factor abrogates life-threatening neutropenia and increases peripheral-blood progenitor-cell mobilization after epirubicin, paclitaxel, and cisplatin combination chemotherapy: results of a randomized comparison. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  V. Bours,et al.  Peripheral blood progenitor cell collections in cancer patients: analysis of factors affecting the yields. , 1999, Haematologica.

[10]  N. Russell,et al.  Stem cell mobilisation in lymphoproliferative diseases , 1998, Bone Marrow Transplantation.

[11]  J. Radford,et al.  Randomized comparison of progenitor-cell mobilization using chemotherapy, stem-cell factor, and filgrastim or chemotherapy plus filgrastim alone in patients with ovarian cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  B. Sautois,et al.  Hematopoietic recovery in cancer patients after transplantation of autologous peripheral blood CD34+ cells or unmanipulated peripheral blood stem and progenitor cells , 1998, Transfusion.

[13]  B. McAneny,et al.  Mobilization and harvesting of peripheral blood stem cells: randomized evaluations of different doses of filgrastim , 1998, British journal of haematology.

[14]  J. Biggs,et al.  A randomised, blinded, placebo-controlled, dose escalation study of the tolerability and efficacy of filgrastim for haemopoietic stem cell mobilisation in patients with severe active rheumatoid arthritis , 1998, Bone Marrow Transplantation.

[15]  C. Begley.  Clinical Studies with Megakaryocyte Growth and Development Factor (Mpl-ligand) , 1997, Thrombosis and Haemostasis.

[16]  R. Bouabdallah,et al.  Autologous transplantation of blood stem cells mobilized with filgrastim alone in 93 patients with malignancies: the number of CD34+ cells reinfused is the only factor predicting both granulocyte and platelet recovery. , 1996, Journal of hematotherapy.

[17]  N. Schmitz,et al.  Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients , 1996, The Lancet.

[18]  A. Hagenbeek,et al.  Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. , 1995, The New England journal of medicine.

[19]  R. Storb,et al.  Factors that influence collection and engraftment of autologous peripheral-blood stem cells. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  B. Barlogie,et al.  Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients. , 1995, Blood.

[21]  B. Teicher,et al.  A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  B. Teicher,et al.  Preclinical studies and clinical correlation of the effect of alkylating dose. , 1988, Cancer research.

[23]  M. Levine,et al.  Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.